8-KMaterial AgreementsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 9, 2007)

Filed November 9, 2007For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on November 8, 2007, reporting on a material definitive agreement related to the issuance of senior notes. The company entered into an Underwriting Agreement and a Pricing Agreement to issue a substantial amount of debt across three different maturities: $1 billion in 5.150% Notes due 2012, $1.5 billion in 5.600% Notes due 2017, and $1 billion in 6.150% Notes due 2037, totaling $3.5 billion in aggregate principal amount. This issuance is part of Abbott's existing shelf registration statement filed in February 2006, indicating a strategic move to secure long-term financing. Investors should note the specific coupon rates and maturity dates for each tranche of debt, as these details will impact the company's future interest expenses and debt repayment schedule. The filing also lists various exhibits, including the underwriting and pricing agreements, forms of the notes, and legal opinions, which provide further details on the terms and conditions of this significant debt offering.

Key Highlights

  • 1Abbott Laboratories entered into agreements to issue $3.5 billion in senior notes.
  • 2The debt issuance is comprised of three tranches: $1 billion due 2012 (5.150% coupon), $1.5 billion due 2017 (5.600% coupon), and $1 billion due 2037 (6.150% coupon).
  • 3The issuance of these notes is registered under a prior Form S-3 shelf registration statement filed in February 2006.
  • 4The agreements were executed on November 6, 2007.
  • 5Key parties involved in underwriting include Morgan Stanley & Co. Incorporated, BNP Paribas Securities Corp., Citigroup Global Markets Inc., and Wachovia Capital Markets, LLC.
  • 6The filing includes exhibits detailing the underwriting agreement, pricing agreement, and forms of the issued debt securities.

Frequently Asked Questions

Abbott Laboratories is issuing a total of $3.5 billion in aggregate principal amount of senior notes.

The new notes are issued in three series: $1 billion of 5.150% Notes due November 30, 2012; $1.5 billion of 5.600% Notes due November 30, 2017; and $1 billion of 6.150% Notes due November 30, 2037.

This issuance will increase Abbott's total debt and its annual interest expense. The proceeds from the notes are not specified in this filing, but typically such debt is issued for general corporate purposes, potential acquisitions, or refinancing existing debt. Investors should monitor the company's balance sheet and cash flow statements in future filings for the impact of this increased leverage.

This debt issuance is part of an existing shelf registration statement on Form S-3 that Abbott filed with the SEC on February 28, 2006, which allows the company to offer debt securities from time to time.